Mach 1 Financial Group LLC Reduces Holdings in Pfizer Inc. (NYSE:PFE)

Mach 1 Financial Group LLC cut its stake in shares of Pfizer Inc. (NYSE:PFE) by 5.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 31,234 shares of the biopharmaceutical company’s stock after selling 1,755 shares during the quarter. Mach 1 Financial Group LLC’s holdings in Pfizer were worth $899,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently bought and sold shares of the stock. Bfsg LLC lifted its holdings in Pfizer by 5.9% in the 3rd quarter. Bfsg LLC now owns 168,804 shares of the biopharmaceutical company’s stock worth $5,599,000 after buying an additional 9,442 shares during the period. Schmidt P J Investment Management Inc. lifted its holdings in Pfizer by 7.0% in the 3rd quarter. Schmidt P J Investment Management Inc. now owns 10,286 shares of the biopharmaceutical company’s stock worth $321,000 after buying an additional 677 shares during the period. Ascent Wealth Partners LLC lifted its holdings in Pfizer by 2.5% in the 3rd quarter. Ascent Wealth Partners LLC now owns 42,699 shares of the biopharmaceutical company’s stock worth $1,416,000 after buying an additional 1,040 shares during the period. Avestar Capital LLC lifted its holdings in Pfizer by 3.7% in the 3rd quarter. Avestar Capital LLC now owns 17,160 shares of the biopharmaceutical company’s stock worth $569,000 after buying an additional 606 shares during the period. Finally, Lake Street Financial LLC lifted its holdings in Pfizer by 22.3% in the 3rd quarter. Lake Street Financial LLC now owns 55,021 shares of the biopharmaceutical company’s stock worth $1,766,000 after buying an additional 10,047 shares during the period. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have weighed in on PFE shares. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a report on Monday, April 15th. TD Cowen lowered Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price for the company. in a research report on Thursday, January 4th. Guggenheim began coverage on Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price for the company. Finally, Argus lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Eleven equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $36.33.

Pfizer Stock Down 0.1 %

Shares of Pfizer stock traded down $0.03 on Tuesday, reaching $25.61. The company’s stock had a trading volume of 37,889,007 shares, compared to its average volume of 41,962,758. The company has a market capitalization of $145.02 billion, a price-to-earnings ratio of 71.14, a P/E/G ratio of 1.14 and a beta of 0.61. The firm’s fifty day simple moving average is $26.88 and its two-hundred day simple moving average is $28.26. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $40.37. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. The business had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The company’s quarterly revenue was down 41.3% compared to the same quarter last year. During the same quarter last year, the company earned $1.14 EPS. Equities analysts anticipate that Pfizer Inc. will post 2.24 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be issued a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.56%. The ex-dividend date of this dividend is Thursday, May 9th. Pfizer’s payout ratio is 466.67%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.